AstraZeneca Pharma India gets DCGI nod to market diabetes drug
The product is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes, AstraZeneca Pharma India said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Diabetes | Diabetes Type 2 | Diets | Endocrinology | India Health | Nutrition | Pharmaceuticals | Sports Medicine